ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2972

Risk of Myocardial Infarction and Cerebrovascular Accident in Ankylosing Spondylitis: A General Population-Based Study

Anthony So1, Jonathan Chan2, Eric C. Sayre3 and J. Antonio Avina-Zubieta3,4, 1University of British Columbia, Vancouver, BC, Canada, 2Rheumatology, University of British Columbia, Vancouver, BC, Canada, 3Arthritis Research Canada, Richmond, BC, Canada, 4Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Cardiovascular disease, Cerebrovascular disease, population studies and spondylarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Wednesday, November 8, 2017

Title: Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment V

Session Type: ACR Concurrent Abstract Session

Session Time: 11:00AM-12:30PM

Background/Purpose: There is conflicting data on the risk of myocardial infarction (MI) and cerebrovascular accidents (CVA) in patients with Ankylosing Spondylitis (AS). This study attempts to assess the future risk of newly recorded MI and CVA events among incident cases of AS compared to non-AS controls from the general population by utilizing physician billing, medication, and hospitalization data that covers the entire province of British Columbia (BC), Canada.

Methods: Our data includes all outpatient visits and hospitalizations (1990-2012) and all dispensed medications (1996-2012) for all BC residents. We conducted a retrospective matched cohort study of all patients > 18 years of age satisfying the following criteria: 1) two ICD-9 or 10 codes (720.0 or M45) for AS at least two months apart and within a 2-year period by any physician or hospitalization; 2) all AS cases had at least a 7-year run-in period before the 1st ICD code for AS in order to consider the case as incident. Each AS patient was matched with up to 10 controls by birth year, sex, and entry cohort time. The outcomes were a newly recorded MI (ICD-9-CM: 410 or ICD-10-CM: I21) or CVA (ICD-9 codes: 433-434, ICD-10 codes: I63-I66) event from hospital or death certificates. We estimated relative risks (RRs), adjusting for age, sex, and entry cohort time as well as multivariable models adjusting for confounders including glucocorticoids and non-steroidal anti-inflammatory drugs using a Cox proportional hazard model.

Results: 7,190 individuals with newly diagnosed AS were identified (48.7% female, mean age of 45.8 yrs). 7,148 and 7,107 were free of previous CVA/MI, respectively. 80 developed CVA (incidence rate= 1.8 per 1000 patient years) and 115 had MI (incidence rate= 2.6 per 1,000 patient years) (Table 1). The age-, sex-, and entry-time-matched RR for CVA was 1.60 (95% CI, 1.25-2.03) and MI was 1.52 (95% CI, 1.24-1.85). When adjusted for cardiovascular risk factors (obesity, angina, COPD, hospitalizations in year before index date, Charlson’s comorbidity index, oral glucocorticoids, cardiovascular drugs, anti-diabetic medication, HRT, contraceptives, fibrates, statins, NSAIDs, and Cox-2 inhibitors), the estimated RR was 1.34 (1.04-1.73) for CVA and 1.21 (0.98-1.49) for MI.

Conclusion: This large population-based study demonstrates an increased risk of CVA, but not for MI. These findings support that increased monitoring for this potentially fatal outcome and its modifiable risk factors is warranted for AS patients.

Table 1: Relative risk of incident CVA and MI according to AS status

AS

(N=7,148)

Non-AS

(N=71,489)

CVA events, n

80

492

Incidence Rate of CVA /1000 Person-Years

1.81

1.13

Incidence Rate Ratio of CVA (95% CI)

1.60 (1.25-2.03)

1.0

Multivariable RR of CVA (95% CI)

1.34 (1.04-1.73)

1.0

AS

(N=7,107)

Non-AS

(N=71,033)

MI events, n

115

748

Incidence Rate of MI /1000 Person-Years

2.62

1.73

Incidence Rate Ratio of MI (95% CI)

1.52 (1.24-1.85)

1.0

Multivariable RR of MI (95% CI)

1.21 (0.98-1.49)

1.0


Disclosure: A. So, None; J. Chan, None; E. C. Sayre, None; J. A. Avina-Zubieta, None.

To cite this abstract in AMA style:

So A, Chan J, Sayre EC, Avina-Zubieta JA. Risk of Myocardial Infarction and Cerebrovascular Accident in Ankylosing Spondylitis: A General Population-Based Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/risk-of-myocardial-infarction-and-cerebrovascular-accident-in-ankylosing-spondylitis-a-general-population-based-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-of-myocardial-infarction-and-cerebrovascular-accident-in-ankylosing-spondylitis-a-general-population-based-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology